12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M (CAD) for Altemia ® VANCOUVER, British Columbia / Jan 08, 2024 / Business Wire / Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases... Read More